Global Atypical Hemolytic Uremic Syndrome Drug Market Insights and Forecast to 2031

Report ID: 1564048 | Published Date: Sep 2024 | No. of Page: 94 | Base Year: 2023 | Rating: 3.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Atypical Hemolytic Uremic Syndrome Drug Product Introduction
    1.2 Market by Type
        1.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 ALN-CC5
        1.2.3 CCX-168
        1.2.4 ET-006
        1.2.5 ETR-001
        1.2.6 Mubodina
        1.2.7 OMS-72
        1.2.8 Others
    1.3 Market by Application
        1.3.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Clinic
        1.3.3 Hospital
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Estimates and Forecasts 2017-2028
    2.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Estimates and Forecasts 2017-2028
    2.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region
        2.4.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2017-2022)
        2.4.2 Global Sales Atypical Hemolytic Uremic Syndrome Drug by Region (2023-2028)
    2.5 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region
        2.5.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2017-2022)
        2.5.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Manufacturers
        3.1.1 Global Top Atypical Hemolytic Uremic Syndrome Drug Manufacturers by Sales (2017-2022)
        3.1.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Atypical Hemolytic Uremic Syndrome Drug in 2021
    3.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Manufacturers
        3.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Manufacturers (2017-2022)
        3.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Atypical Hemolytic Uremic Syndrome Drug Revenue in 2021
    3.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Atypical Hemolytic Uremic Syndrome Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type
        4.1.1 Global Atypical Hemolytic Uremic Syndrome Drug Historical Sales by Type (2017-2022)
        4.1.2 Global Atypical Hemolytic Uremic Syndrome Drug Forecasted Sales by Type (2023-2028)
        4.1.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2017-2028)
    4.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type
        4.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Historical Revenue by Type (2017-2022)
        4.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2017-2028)
    4.3 Global Atypical Hemolytic Uremic Syndrome Drug Price by Type
        4.3.1 Global Atypical Hemolytic Uremic Syndrome Drug Price by Type (2017-2022)
        4.3.2 Global Atypical Hemolytic Uremic Syndrome Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application
        5.1.1 Global Atypical Hemolytic Uremic Syndrome Drug Historical Sales by Application (2017-2022)
        5.1.2 Global Atypical Hemolytic Uremic Syndrome Drug Forecasted Sales by Application (2023-2028)
        5.1.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2017-2028)
    5.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application
        5.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Historical Revenue by Application (2017-2022)
        5.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2017-2028)
    5.3 Global Atypical Hemolytic Uremic Syndrome Drug Price by Application
        5.3.1 Global Atypical Hemolytic Uremic Syndrome Drug Price by Application (2017-2022)
        5.3.2 Global Atypical Hemolytic Uremic Syndrome Drug Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Atypical Hemolytic Uremic Syndrome Drug Market Size by Type
        6.1.1 North America Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2017-2028)
        6.1.2 North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2017-2028)
    6.2 North America Atypical Hemolytic Uremic Syndrome Drug Market Size by Application
        6.2.1 North America Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2017-2028)
        6.2.2 North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2017-2028)
    6.3 North America Atypical Hemolytic Uremic Syndrome Drug Market Size by Country
        6.3.1 North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2017-2028)
        6.3.2 North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Atypical Hemolytic Uremic Syndrome Drug Market Size by Type
        7.1.1 Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2017-2028)
        7.1.2 Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2017-2028)
    7.2 Europe Atypical Hemolytic Uremic Syndrome Drug Market Size by Application
        7.2.1 Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2017-2028)
        7.2.2 Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2017-2028)
    7.3 Europe Atypical Hemolytic Uremic Syndrome Drug Market Size by Country
        7.3.1 Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2017-2028)
        7.3.2 Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Market Size by Type
        8.1.1 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2017-2028)
        8.1.2 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2017-2028)
    8.2 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Market Size by Application
        8.2.1 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2017-2028)
        8.2.2 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2017-2028)
    8.3 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Market Size by Region
        8.3.1 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2017-2028)
        8.3.2 Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Atypical Hemolytic Uremic Syndrome Drug Market Size by Type
        9.1.1 Latin America Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2017-2028)
        9.1.2 Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2017-2028)
    9.2 Latin America Atypical Hemolytic Uremic Syndrome Drug Market Size by Application
        9.2.1 Latin America Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2017-2028)
        9.2.2 Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2017-2028)
    9.3 Latin America Atypical Hemolytic Uremic Syndrome Drug Market Size by Country
        9.3.1 Latin America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2017-2028)
        9.3.2 Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Market Size by Type
        10.1.1 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2017-2028)
    10.2 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Market Size by Application
        10.2.1 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2017-2028)
    10.3 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Market Size by Country
        10.3.1 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Achillion Pharmaceuticals Inc
        11.1.1 Achillion Pharmaceuticals Inc Corporation Information
        11.1.2 Achillion Pharmaceuticals Inc Overview
        11.1.3 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Achillion Pharmaceuticals Inc Recent Developments
    11.2 Akari Therapeutics Plc
        11.2.1 Akari Therapeutics Plc Corporation Information
        11.2.2 Akari Therapeutics Plc Overview
        11.2.3 Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 Akari Therapeutics Plc Recent Developments
    11.3 Alexion Pharmaceuticals Inc
        11.3.1 Alexion Pharmaceuticals Inc Corporation Information
        11.3.2 Alexion Pharmaceuticals Inc Overview
        11.3.3 Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Alexion Pharmaceuticals Inc Recent Developments
    11.4 Amgen Inc
        11.4.1 Amgen Inc Corporation Information
        11.4.2 Amgen Inc Overview
        11.4.3 Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Amgen Inc Recent Developments
    11.5 ChemoCentryx Inc
        11.5.1 ChemoCentryx Inc Corporation Information
        11.5.2 ChemoCentryx Inc Overview
        11.5.3 ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 ChemoCentryx Inc Recent Developments
    11.6 greenovation Biotech GmbH
        11.6.1 greenovation Biotech GmbH Corporation Information
        11.6.2 greenovation Biotech GmbH Overview
        11.6.3 greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 greenovation Biotech GmbH Recent Developments
    11.7 Kedrion SpA
        11.7.1 Kedrion SpA Corporation Information
        11.7.2 Kedrion SpA Overview
        11.7.3 Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Kedrion SpA Recent Developments
    11.8 Omeros Corp
        11.8.1 Omeros Corp Corporation Information
        11.8.2 Omeros Corp Overview
        11.8.3 Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Omeros Corp Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Atypical Hemolytic Uremic Syndrome Drug Industry Chain Analysis
    12.2 Atypical Hemolytic Uremic Syndrome Drug Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Atypical Hemolytic Uremic Syndrome Drug Production Mode & Process
    12.4 Atypical Hemolytic Uremic Syndrome Drug Sales and Marketing
        12.4.1 Atypical Hemolytic Uremic Syndrome Drug Sales Channels
        12.4.2 Atypical Hemolytic Uremic Syndrome Drug Distributors
    12.5 Atypical Hemolytic Uremic Syndrome Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Atypical Hemolytic Uremic Syndrome Drug Industry Trends
    13.2 Atypical Hemolytic Uremic Syndrome Drug Market Drivers
    13.3 Atypical Hemolytic Uremic Syndrome Drug Market Challenges
    13.4 Atypical Hemolytic Uremic Syndrome Drug Market Restraints
14 Key Findings in The Global Atypical Hemolytic Uremic Syndrome Drug Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer

List of Tables
    Table 1. Global Atypical Hemolytic Uremic Syndrome Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of ALN-CC5
    Table 3. Major Manufacturers of CCX-168
    Table 4. Major Manufacturers of ET-006
    Table 5. Major Manufacturers of ETR-001
    Table 6. Major Manufacturers of Mubodina
    Table 7. Major Manufacturers of OMS-72
    Table 8. Major Manufacturers of Others
    Table 9. Global Atypical Hemolytic Uremic Syndrome Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 10. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 11. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2017-2022) & (K Pcs)
    Table 12. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2017-2022)
    Table 13. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2023-2028) & (K Pcs)
    Table 14. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2023-2028)
    Table 15. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2017-2022) & (US$ Million)
    Table 16. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2017-2022)
    Table 17. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2023-2028) & (US$ Million)
    Table 18. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2023-2028)
    Table 19. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Manufacturers (2017-2022) & (K Pcs)
    Table 20. Global Atypical Hemolytic Uremic Syndrome Drug Sales Share by Manufacturers (2017-2022)
    Table 21. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 22. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Manufacturers (2017-2022)
    Table 23. Atypical Hemolytic Uremic Syndrome Drug Price by Manufacturers (2017-2022) &(USD/Pcs)
    Table 24. Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 25. Global Atypical Hemolytic Uremic Syndrome Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Atypical Hemolytic Uremic Syndrome Drug as of 2021)
    Table 26. Atypical Hemolytic Uremic Syndrome Drug Manufacturing Base Distribution and Headquarters
    Table 27. Manufacturers Atypical Hemolytic Uremic Syndrome Drug Product Offered
    Table 28. Date of Manufacturers Enter into Atypical Hemolytic Uremic Syndrome Drug Market
    Table 29. Mergers & Acquisitions, Expansion Plans
    Table 30. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2017-2022) & (K Pcs)
    Table 31. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2023-2028) & (K Pcs)
    Table 32. Global Atypical Hemolytic Uremic Syndrome Drug Sales Share by Type (2017-2022)
    Table 33. Global Atypical Hemolytic Uremic Syndrome Drug Sales Share by Type (2023-2028)
    Table 34. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 35. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 36. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Type (2017-2022)
    Table 37. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Type (2023-2028)
    Table 38. Atypical Hemolytic Uremic Syndrome Drug Price by Type (2017-2022) & (USD/Pcs)
    Table 39. Global Atypical Hemolytic Uremic Syndrome Drug Price Forecast by Type (2023-2028) & (USD/Pcs)
    Table 40. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2017-2022) & (K Pcs)
    Table 41. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2023-2028) & (K Pcs)
    Table 42. Global Atypical Hemolytic Uremic Syndrome Drug Sales Share by Application (2017-2022)
    Table 43. Global Atypical Hemolytic Uremic Syndrome Drug Sales Share by Application (2023-2028)
    Table 44. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 45. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 46. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Application (2017-2022)
    Table 47. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Application (2023-2028)
    Table 48. Atypical Hemolytic Uremic Syndrome Drug Price by Application (2017-2022) & (USD/Pcs)
    Table 49. Global Atypical Hemolytic Uremic Syndrome Drug Price Forecast by Application (2023-2028) & (USD/Pcs)
    Table 50. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2017-2022) & (K Pcs)
    Table 51. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2023-2028) & (K Pcs)
    Table 52. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 53. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 54. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2017-2022) & (K Pcs)
    Table 55. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2023-2028) & (K Pcs)
    Table 56. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 57. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 58. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2017-2022) & (K Pcs)
    Table 59. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2023-2028) & (K Pcs)
    Table 60. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 61. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 62. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2017-2022) & (K Pcs)
    Table 63. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2023-2028) & (K Pcs)
    Table 64. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 65. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 66. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2017-2022) & (K Pcs)
    Table 67. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2023-2028) & (K Pcs)
    Table 68. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 69. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 70. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2017-2022) & (K Pcs)
    Table 71. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2023-2028) & (K Pcs)
    Table 72. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 73. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 74. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2017-2022) & (K Pcs)
    Table 75. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2023-2028) & (K Pcs)
    Table 76. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 77. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 78. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2017-2022) & (K Pcs)
    Table 79. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2023-2028) & (K Pcs)
    Table 80. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 81. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 82. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2017-2022) & (K Pcs)
    Table 83. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2023-2028) & (K Pcs)
    Table 84. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2017-2022) & (US$ Million)
    Table 85. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2023-2028) & (US$ Million)
    Table 86. Latin America Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2017-2022) & (K Pcs)
    Table 87. Latin America Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2023-2028) & (K Pcs)
    Table 88. Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 89. Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 90. Latin America Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2017-2022) & (K Pcs)
    Table 91. Latin America Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2023-2028) & (K Pcs)
    Table 92. Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 93. Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 94. Latin America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2017-2022) & (K Pcs)
    Table 95. Latin America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2023-2028) & (K Pcs)
    Table 96. Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 97. Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 98. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2017-2022) & (K Pcs)
    Table 99. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2023-2028) & (K Pcs)
    Table 100. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 101. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 102. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2017-2022) & (K Pcs)
    Table 103. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2023-2028) & (K Pcs)
    Table 104. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 105. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 106. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2017-2022) & (K Pcs)
    Table 107. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2023-2028) & (K Pcs)
    Table 108. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 109. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 110. Achillion Pharmaceuticals Inc Corporation Information
    Table 111. Achillion Pharmaceuticals Inc Description and Major Businesses
    Table 112. Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 113. Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 114. Achillion Pharmaceuticals Inc Recent Developments
    Table 115. Akari Therapeutics Plc Corporation Information
    Table 116. Akari Therapeutics Plc Description and Major Businesses
    Table 117. Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 118. Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 119. Akari Therapeutics Plc Recent Developments
    Table 120. Alexion Pharmaceuticals Inc Corporation Information
    Table 121. Alexion Pharmaceuticals Inc Description and Major Businesses
    Table 122. Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 123. Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 124. Alexion Pharmaceuticals Inc Recent Developments
    Table 125. Amgen Inc Corporation Information
    Table 126. Amgen Inc Description and Major Businesses
    Table 127. Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 128. Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 129. Amgen Inc Recent Developments
    Table 130. ChemoCentryx Inc Corporation Information
    Table 131. ChemoCentryx Inc Description and Major Businesses
    Table 132. ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 133. ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 134. ChemoCentryx Inc Recent Developments
    Table 135. greenovation Biotech GmbH Corporation Information
    Table 136. greenovation Biotech GmbH Description and Major Businesses
    Table 137. greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 138. greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 139. greenovation Biotech GmbH Recent Developments
    Table 140. Kedrion SpA Corporation Information
    Table 141. Kedrion SpA Description and Major Businesses
    Table 142. Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 143. Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 144. Kedrion SpA Recent Developments
    Table 145. Omeros Corp Corporation Information
    Table 146. Omeros Corp Description and Major Businesses
    Table 147. Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 148. Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 149. Omeros Corp Recent Developments
    Table 150. Key Raw Materials Lists
    Table 151. Raw Materials Key Suppliers Lists
    Table 152. Atypical Hemolytic Uremic Syndrome Drug Distributors List
    Table 153. Atypical Hemolytic Uremic Syndrome Drug Customers List
    Table 154. Atypical Hemolytic Uremic Syndrome Drug Market Trends
    Table 155. Atypical Hemolytic Uremic Syndrome Drug Market Drivers
    Table 156. Atypical Hemolytic Uremic Syndrome Drug Market Challenges
    Table 157. Atypical Hemolytic Uremic Syndrome Drug Market Restraints
    Table 158. Research Programs/Design for This Report
    Table 159. Key Data Information from Secondary Sources
    Table 160. Key Data Information from Primary Sources
List of Figures
    Figure 1. Atypical Hemolytic Uremic Syndrome Drug Product Picture
    Figure 3. Global Atypical Hemolytic Uremic Syndrome Drug Market Share by Type in 2021 & 2028
    Figure 3. ALN-CC5 Product Picture
    Figure 4. CCX-168 Product Picture
    Figure 5. ET-006 Product Picture
    Figure 6. ETR-001 Product Picture
    Figure 7. Mubodina Product Picture
    Figure 8. OMS-72 Product Picture
    Figure 9. Others Product Picture
    Figure 10. Global Atypical Hemolytic Uremic Syndrome Drug Market Share by Application in 2021 & 2028
    Figure 11. Clinic
    Figure 12. Hospital
    Figure 13. Others
    Figure 14. Atypical Hemolytic Uremic Syndrome Drug Report Years Considered
    Figure 15. Global Atypical Hemolytic Uremic Syndrome Drug Sales 2017-2028 (K Pcs)
    Figure 16. Global Atypical Hemolytic Uremic Syndrome Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 17. Global Atypical Hemolytic Uremic Syndrome Drug Revenue 2017-2028 (US$ Million)
    Figure 18. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 19. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2017-2022)
    Figure 20. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2023-2028)
    Figure 21. North America Atypical Hemolytic Uremic Syndrome Drug Sales YoY (2017-2028) & (K Pcs)
    Figure 22. North America Atypical Hemolytic Uremic Syndrome Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 23. Europe Atypical Hemolytic Uremic Syndrome Drug Sales YoY (2017-2028) & (K Pcs)
    Figure 24. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 25. Asia-Pacific Atypical Hemolytic Uremic Syndrome Drug Sales YoY (2017-2028) & (K Pcs)
    Figure 26. Asia-Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 27. Latin America Atypical Hemolytic Uremic Syndrome Drug Sales YoY (2017-2028) & (K Pcs)
    Figure 28. Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 29. Middle East & Africa Atypical Hemolytic Uremic Syndrome Drug Sales YoY (2017-2028) & (K Pcs)
    Figure 30. Middle East & Africa Atypical Hemolytic Uremic Syndrome Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 31. The Atypical Hemolytic Uremic Syndrome Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 32. The Top 5 and 10 Largest Manufacturers of Atypical Hemolytic Uremic Syndrome Drug in the World: Market Share by Atypical Hemolytic Uremic Syndrome Drug Revenue in 2021
    Figure 33. Global Atypical Hemolytic Uremic Syndrome Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 34. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2017-2028)
    Figure 35. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2017-2028)
    Figure 36. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2017-2028)
    Figure 37. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2017-2028)
    Figure 38. North America Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2017-2028)
    Figure 39. North America Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2017-2028)
    Figure 40. North America Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2017-2028)
    Figure 41. North America Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2017-2028)
    Figure 42. North America Atypical Hemolytic Uremic Syndrome Drug Sales Share by Country (2017-2028)
    Figure 43. North America Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country (2017-2028)
    Figure 44. U.S. Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 45. Canada Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 46. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2017-2028)
    Figure 47. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2017-2028)
    Figure 48. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2017-2028)
    Figure 49. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2017-2028)
    Figure 50. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Share by Country (2017-2028)
    Figure 51. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country (2017-2028)
    Figure 52. Germany Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 53. France Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 54. U.K. Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 55. Italy Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 56. Russia Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 57. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2017-2028)
    Figure 58. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2017-2028)
    Figure 59. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2017-2028)
    Figure 60. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2017-2028)
    Figure 61. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Sales Share by Region (2017-2028)
    Figure 62. Asia Pacific Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Region (2017-2028)
    Figure 63. China Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 64. Japan Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 65. South Korea Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 66. India Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 67. Australia Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 68. Taiwan Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 69. Indonesia Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 70. Thailand Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 71. Malaysia Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 72. Philippines Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 73. Latin America Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2017-2028)
    Figure 74. Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2017-2028)
    Figure 75. Latin America Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2017-2028)
    Figure 76. Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2017-2028)
    Figure 77. Latin America Atypical Hemolytic Uremic Syndrome Drug Sales Share by Country (2017-2028)
    Figure 78. Latin America Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country (2017-2028)
    Figure 79. Mexico Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 80. Brazil Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 81. Argentina Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 82. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2017-2028)
    Figure 83. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2017-2028)
    Figure 84. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2017-2028)
    Figure 85. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2017-2028)
    Figure 86. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales Share by Country (2017-2028)
    Figure 87. Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country (2017-2028)
    Figure 88. Turkey Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 89. Saudi Arabia Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 90. UAE Atypical Hemolytic Uremic Syndrome Drug Revenue (2017-2028) & (US$ Million)
    Figure 91. Atypical Hemolytic Uremic Syndrome Drug Value Chain
    Figure 92. Atypical Hemolytic Uremic Syndrome Drug Production Process
    Figure 93. Channels of Distribution
    Figure 94. Distributors Profiles
    Figure 95. Bottom-up and Top-down Approaches for This Report
    Figure 96. Data Triangulation
    Figure 97. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Achillion Pharmaceuticals Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Amgen Inc
ChemoCentryx Inc
greenovation Biotech GmbH
Kedrion SpA
Omeros Corp
Frequently Asked Questions
Atypical Hemolytic Uremic Syndrome Drug report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Atypical Hemolytic Uremic Syndrome Drug report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Atypical Hemolytic Uremic Syndrome Drug report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Abrasive Material

Abrasive Material market is segmented by Type and by Application. Players, stakeholders, and othe ... Read More